A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

December 7, 2015

Primary Completion Date

October 27, 2016

Study Completion Date

February 10, 2017

Conditions
Hepatitis C Virus InfectionChronic Hepatitis CCompensated Cirrhosis
Interventions
DRUG

ABT-493/ABT-530

Tablet; ABT-493 coformulated with ABT-530

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY